Compare Daito Pharmaceutical Co., Ltd. with Similar Stocks
Dashboard
1
Weak Long Term Fundamental Strength with a -10.52% CAGR growth in Operating Profits over the last 5 years
2
Poor long term growth as Net Sales has grown by an annual rate of 0.93% and Operating profit at -10.52% over the last 5 years
3
Positive results in May 26
4
With ROE of 5.85%, it has a fair valuation with a 0.67 Price to Book Value
5
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 36,675 Million (Small Cap)
11.00
NA
0.00%
0.11
5.85%
0.70
Revenue and Profits:
Net Sales:
13,918 Million
(Quarterly Results - May 2026)
Net Profit:
866 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
10.93%
0%
10.93%
6 Months
-6.44%
0%
-6.44%
1 Year
9.58%
0%
9.58%
2 Years
-40.89%
0%
-40.89%
3 Years
-42.33%
0%
-42.33%
4 Years
-45.67%
0%
-45.67%
5 Years
-62.08%
0%
-62.08%
Daito Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
0.93%
EBIT Growth (5y)
-10.52%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0.51
Net Debt to Equity (avg)
0.15
Sales to Capital Employed (avg)
0.79
Tax Ratio
22.84%
Dividend Payout Ratio
55.80%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.32%
ROE (avg)
7.40%
Valuation key factors
Factor
Value
P/E Ratio
11
Industry P/E
Price to Book Value
0.67
EV to EBIT
11.65
EV to EBITDA
5.17
EV to Capital Employed
0.70
EV to Sales
0.80
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
6.02%
ROE (Latest)
5.85%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - May'26 - YoY
May'26
May'25
Change(%)
Net Sales
13,918.00
14,034.00
-0.83%
Operating Profit (PBDIT) excl Other Income
1,998.00
1,876.00
6.50%
Interest
34.00
38.00
-10.53%
Exceptional Items
-42.00
-164.00
74.39%
Consolidate Net Profit
866.00
675.00
28.30%
Operating Profit Margin (Excl OI)
63.50%
53.60%
0.99%
USD in Million.
Net Sales
YoY Growth in quarter ended May 2026 is -0.83% vs 14.72% in May 2025
Consolidated Net Profit
YoY Growth in quarter ended May 2026 is 28.30% vs -25.66% in May 2025
Annual Results Snapshot (Consolidated) - May'26
May'26
May'25
Change(%)
Net Sales
50,650.00
50,643.00
0.01%
Operating Profit (PBDIT) excl Other Income
8,024.00
6,953.00
15.40%
Interest
130.00
123.00
5.69%
Exceptional Items
36.00
-33.00
209.09%
Consolidate Net Profit
3,136.00
1,765.00
77.68%
Operating Profit Margin (Excl OI)
71.80%
51.80%
2.00%
USD in Million.
Net Sales
YoY Growth in year ended May 2026 is 0.01% vs 7.99% in May 2025
Consolidated Net Profit
YoY Growth in year ended May 2026 is 77.68% vs -44.46% in May 2025
About Daito Pharmaceutical Co., Ltd. 
Daito Pharmaceutical Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






